Navigation Links
Kendle Announces Details Regarding Fourth Quarter and Full-Year 2010 Earnings Conference Call and Webcast
Date:2/25/2011

CINCINNATI, Feb. 25, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL) announced today it will release its fourth quarter and full-year 2010 financial results after the market closes on Wednesday, March 2, 2011. The Company will host a telephone conference call and simultaneous webcast on Thursday, March 3, 2011 at 1:00 p.m. Eastern Time. A question and answer session will follow.

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 946-0716. Participants outside North America should dial (719) 457-2632. All participants should enter conference ID number 5419062. A replay will be available through 5 p.m. Eastern Time on April 4, 2011, by dialing (888) 203-1112 in North America or 719-457-0820 outside of North America and entering conference ID number 5419062.

Webcast Instructions

To access the live webcast, visit

http://ir.kendle.com/phoenix.zhtml?p=irol-eventDetails&c=88712&eventID=3716940.

Instructions for accessing the webcast are provided at the site. The webcast will be archived at www.kendle.com (click on "For Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on April 4, 2011. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the UBS Global Life Sciences Conference
2. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
3. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
4. Kendle Named a Best Place to Work in Greater Cincinnati
5. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
6. Kendle to Present at the 2008 Credit Suisse Health Care Conference
7. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
8. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
9. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
10. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
11. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , Mar 23, 2017 Research ... Products: Global Markets" report to their offering. ... The Global ... $466.6 Billion in 2016 at a CAGR of 8.9%, ... energetic and non-energetic bioproducts into seven major product segments: bio-derived ...
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
Breaking Biology Technology:
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):